Healthcare Advances in Gene Editing Technologies in Healthcare Updated Research Available

Next-generation genome editing tools and improved delivery are bolstering gene editing therapeutics and diagnostics.

INDUSTRY
Healthcare

RELEASE DATE
19-Jan-2023
REGION
Global
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
DA7F-01-00-00-00
SKU
HC03633-GL-TR_27404
Yes
SHARE

Advances in Gene Editing Technologies in Healthcare
Published on: 19-Jan-2023 | SKU: HC03633-GL-TR_27404

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Advancements in gene editing technology are boosting its adoption in various fields, including healthcare, diagnostics, agriculture, and industrial biotechnology. CRISPR, ZFNs, and TALENs are examples of technologies that have revolutionized the gene editing field. Moreover, with constant research efforts, new technologies such as base editing, prime editing, twin prime editing, and PASTE have emerged.
The adoption of gene editing technologies is focused on therapeutics and diagnostics, with CRISPR being the most widely used technology due to the numerous advantages it offers.
Immuno-oncology, blood disorders, and neuro-disorders are just a few of the diseases that gene editing technology targets. In addition, cardiovascular and viral diseases are intriguing areas that gene editing technology has the potential to treat.
A growth driver is the rising need for precise and targeted treatment for currently incurable diseases. Most gene editing companies use CRISPR technology for therapeutic and diagnostic development, mainly because CRISPR has the highest IP and is the most researched technology.
Companies are actively working to overcome the challenges associated with CRISPR technology, which has resulted in the development of novel delivery technologies, new miniaturized Cas molecules, and nuclease expression control. All these advancements accelerate the adoption of gene editing technologies. Increased venture capital and government funding are other factors driving the growth of these technologies.

Key Questions This Study Answers:
•What is gene editing technology?
•What are the growth drivers and restraints for gene editing technologies?
•What are the emerging trends in gene editing-based therapeutics and diagnostics?
•What does the tech innovation landscape look like?
•What are the recent R&D activities and collaborations?
•What are the growth opportunities for companies developing gene editing-based products?

Why Is It Increasingly Difficult To Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Gene Editing Technology Industry

Growth Opportunities Fuel The Growth Pipeline Engine™

Research Context

Research Coverage and Key Questions the Study Will Answer

Research Methodology

Development of Gene Editing Tools

Technology Assessment of Gene Editing Tools

Research Hubs for Gene Editing Technology

Uses of Gene Editing Technology in the Clinic—Therapeutics and Diagnostics

Growth Drivers

Growth Driver Analysis

Growth Restraints

Growth Restraint Analysis

Emerging Trends in the Adoption of Genome Editing in the Clinic

Technology Developments around CRISPR-Cas

Technology Developments around CRISPR-Cas to Improve Delivery

Technology Developments around CRISPR-Cas to Improve Precision

Next-generation Gene Editing Technology

Next-generation Gene Editing Technology (continued)

Next-generation Gene Editing Technology (continued)

Next-generation Gene Editing Technology (continued)

Emerging Participants Working on Next-generation CRISPR Technology

Emerging Technology Developers Leveraging CRISPR

CRISPR/Cas: Applications across Indications

CRISPR/Cas: Applications across Indications (continued)

Major Participants Developing CRISPR-based Therapeutics

Major Participants Developing CRISPR-based Therapeutics (continued)

Development of CRISPR-based Gene Editing as Targeted Antibacterials

Development of CRISPR-based Gene Editing as Targeted Antivirals

Non-CRISPR-based Therapeutics

Major Participants Developing Non-CRISPR-based Therapeutics

Development of Gene Editing Tools in Diagnostics

CRISPR-Cas System-based Diagnostic Tools

CRISPR-Cas System-based Diagnostic Tools (continued)

Gene Editing Strategies: Developments in In Vivo and Ex Vivo Gene Editing Tools

Challenges and Limitations of Gene Editing Delivery Systems

Developments in Gene Editing Delivery

Current Approaches for Gene Editing Delivery

Current Approaches for Gene Editing Delivery (continued)

Developments in Viral Vectors for Gene Editing Delivery

Developments in Viral Vectors for Gene Editing Delivery (continued)

Developments in Nonviral Vectors for Gene Editing Delivery Carriers – Lipid-based Formulations

Developments in Nonviral Vectors for Gene Editing Delivery Carriers – Lipid-based Formulations (continued)

Cell/Cell Component-derived Carriers

Cell/Cell Component-derived Carriers (continued)

Polymer-based Formulations

Peptide-based Formulations

Development of Other Nanoscale Gene Editing Delivery Carriers

Development of Other Nanoscale Gene Editing Delivery Carriers (continued)

Nanoparticles

Nanoparticles (continued)

Development of Physical Methods of Delivery of Gene Editing Therapeutics

Development of Physical Methods of Delivery of Gene Editing Therapeutics (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

Technology Licensing

Technology Licensing(continued)

Acquisitions

Highlights of Gene Edited Therapeutics and Diagnostic Development Collaborations

Significant VC Funding Boosts the Development of Gene Editing Companies (2019-2022)

Significant VC Funding Boosts the Development of Gene Editing Companies (2019-2022) (continued)

Funding Analysis of Gene Editing Companies

Funding Analysis of Gene Editing Companies (continued)

Key Takeaways

Growth Opportunity 1: Advanced Delivery and Formulation Strategies for the Safe and Effective Delivery of Gene Editing Tools

Growth Opportunity 1: Advanced Delivery and Formulation Strategies for the Safe and Effective Delivery of Gene Editing Tools (continued)

Growth Opportunity 2: Emerging Applications of Gene Editing Technologies Open Profitable Growth Opportunities

Growth Opportunity 2: Emerging Applications of Gene Editing Technologies Open Profitable Growth Opportunities (continued)

Growth Opportunity 3: Advancements in Technologies to Make Them More Precise, Efficient, and Safe

Growth Opportunity 3: Advancements in Technologies to Make Them More Precise, Efficient, and Safe (continued)

Future Outlook of Gene Editing Applications beyond Healthcare

Future Outlook of Gene Editing Applications beyond Healthcare (continued)

Different Gene Editing Tools under Clinical Study through the In Vivo and Ex Vivo Approaches

Different Gene Editing Tools under Clinical Study through the In Vivo and Ex Vivo Approaches (continued)

Existing Gene Editing Delivery Vectors

Existing Gene Editing Delivery Vectors (continued)

Technology Readiness Levels (TRL): Explanation

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

25 Sep 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Diagnostic Solutions, and Implantables

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, diagnostic solutions, and implantables.The issue features advanced medical devices such as peritoneal dialysis fluid system, cold sterilization-based au...

23 Sep 2026   |   Global   |   Technology Research

Programmable Epigenome Editing for Disease Reversal

Programmable epigenome editing is developing as a distinct approach to controlling gene activity without changing the underlying DNA sequence. This report examines the landscape from the core editing technologies and delivery systems through the companies, academic programs and therapeutic applicati...

21 Sep 2026   |   Europe   |   Market Research

HLTH Europe 2026: Five Key Takeaways and Growth Opportunities

HLTH Europe 2026, held in Amsterdam, brought together more than 5,000 stakeholders spanning providers, payers, health systems, technology vendors, start-ups, investors, and policymakers, providing a comprehensive view of the evolving European digital health landscape. Across conference sessions and ...

21 Sep 2026   |   Global   |   Frost Radar

Frost Radar: Smart Nutraceuticals for Brain Health, 2026

This Frost Radar evaluates the evolving smart nutraceuticals landscape as consumer awareness of cognitive health, lifestyle-related stress, and healthy aging creates demand for scientifically validated, natural, and multifunctional brain health solutions. The market remains fragmented, with differen...

18 Sep 2026   |   Global   |   Frost Radar

Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026

Laboratory information management systems (LIMS) have been used in life sciences since laboratories began digitizing sample tracking and data management in the 1970s. Modern LIMS solutions enhance efficiency by automating workflows, improving data accuracy, and enabling seamless integration and offe...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Advancements in gene editing technology are boosting its adoption in various fields, including healthcare, diagnostics, agriculture, and industrial biotechnology. CRISPR, ZFNs, and TALENs are examples of technologies that have revolutionized the gene editing field. Moreover, with constant research efforts, new technologies such as base editing, prime editing, twin prime editing, and PASTE have emerged. The adoption of gene editing technologies is focused on therapeutics and diagnostics, with CRISPR being the most widely used technology due to the numerous advantages it offers. Immuno-oncology, blood disorders, and neuro-disorders are just a few of the diseases that gene editing technology targets. In addition, cardiovascular and viral diseases are intriguing areas that gene editing technology has the potential to treat. A growth driver is the rising need for precise and targeted treatment for currently incurable diseases. Most gene editing companies use CRISPR technology for therapeutic and diagnostic development, mainly because CRISPR has the highest IP and is the most researched technology. Companies are actively working to overcome the challenges associated with CRISPR technology, which has resulted in the development of novel delivery technologies, new miniaturized Cas molecules, and nuclease expression control. All these advancements accelerate the adoption of gene editing technologies. Increased venture capital and government funding are other factors driving the growth of these technologies. Key Questions This Study Answers: •What is gene editing technology •What are the growth drivers and restraints for gene editing technologies •What are the emerging trends in gene editing-based therapeutics and diagnostics •What does the tech innovation landscape look like •What are the recent R&D activities and collaborations •What are the growth opportunities for companies developing gene editing-based products
More Information
Deliverable Type Technology Research
Author Priyanka Jain
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Gene Editing Technologies
Keyword 2 Crispr Gene Editing
Keyword 3 Gene Editing Systems
Podcast No
WIP Number DA7F-01-00-00-00

Advances in Gene Editing Technologies in Healthcare

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03633-GL-TR_27404